Article
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.
Melanoma research - 1 Dec 2022
Ismail Rawa K, Suijkerbuijk Karijn P M, de Boer Anthonius, van Dartel Maaike, Hilarius Doranne L, Pasmooij A M G, van Zeijl Michiel C T, Aarts Maureen J B, van den Berkmortel Franchette W P J, Blank Christian U, Boers-Sonderen Marye J, de Groot Jan W B, Haanen John B A G, Hospers Geke A P, Kapiteijn Ellen, Piersma Djura, van Rijn Rozemarijn S, van der Veldt Astrid A M, Vreugdenhil Art, Westgeest Hans, van den Eertwegh Alfons J, Wouters Michel W J M
Abstract excerpt
Recent results of patients with advanced melanoma treated with first-line BRAF-MEK inhibitors in clinical trials showed 5-year survival in one-third of patients with a median overall survival (OS) of more than 2 years. This study aimed to investigate these patients' real-world survival and identify the characteristics of long-term survivors. The study population consisted of patients with advanced cutaneous...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.